Neoleukin Therapeutics Inc (NAS:NLTX)
$ 3.49 0 (0%) Market Cap: 8.20 Mil Enterprise Value: -35.02 Mil PE Ratio: 0 PB Ratio: 0.10 GF Score: 22/100

Capricor Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 30, 2021 / 01:20PM GMT
Release Date Price: $144.6 (+0.14%)
Kristen Kluska
Cantor Fitzgerald - Analyst

Hello, everyone. I'm Kristen Kluska, one of the biotechnology analysts at Cantor. It's my pleasure to host Capricor Therapeutics today. Joining me on our fireside chat is Dr. Linda Marban, the President, CEO, Director; and AJ Bergmann, the CFO. Thank you for joining us and for being at our conference.

Linda Marban
Capricor Therapeutics, Inc. - President & CEO

We're delighted. Thank you, Kristin.

Questions & Answers

Kristen Kluska;Linda Marban
Cantor Fitzgerald - Analyst;Capricor Therapeutics, Inc. -

Great. So let's start with some questions about the platform and the technologies, specifically related to your cell therapy program. I think this is a space where companies have traditionally all been viewed under the same umbrella around stem and cell therapies. So, could you please walk through the differentiated profile of CAP-1002, which consists of allogeneic cardiosphere-derived cells that work to secrete exosomes?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot